Associate Professor Wendy Ingman

Associate Professor Wendy Ingman
 Position Ext-Funded Research Fellow (D)
 Org Unit Surgical Specialities
 Email wendy.ingman@adelaide.edu.au
 Telephone 0 8222 6141
 Location QEH - Basil Hetzel Institute ,   North Terrace
  • Biography/ Background


    The Hospital Research Foundation Associate Professor of Breast Cancer Research

    Head of the Breast Biology and Cancer Unit

    A/Prof Wendy Ingman graduated from a PhD at the ÐÓ°ÉÖ±²¥ of Adelaide in 2002 and conducted postdoctoral training as an NHMRC CJ Martin Fellow at the Albert Einstein College of Medicine in New York, USA, returning to Adelaide in 2005. Wendy made the transition to independent researcher in 2009 with an NHMRC New Investigator Project grant. In 2011 she was appointed an NBCF Early Career Fellow and THRF A/Prof of Breast Cancer Research, and established a laboratory at The Queen Elizabeth Hospital which is her current appointment. The Unit investigates breast biology and how disease states of the breast occur. 

    The Breast Biology and Cancer Unit is located at the Basil Hetzel Institute within The Queen Elizabeth Hospital.

    Research Interests


    Breast Cancer Risk and Prevention

    Breast cancer places an incredible burden on ÐÓ°ÉÖ±²¥n women. Every year, around 18,000 ÐÓ°ÉÖ±²¥n women are diagnosed with breast cancer alone - a disease that devastates women's lives and is often fatal.

    If we are to prevent and treat breast cancer, we must better understand how the disease develops. Breast density (also known as mammographic density) is the percentage of white and bright regions on a mammogram. Breast density is not related to how breasts look or feel and can only be assessed by mammogram. Forty three percent of women have "Heterogenously Dense" or "Extremely Dense" breasts, which together are termed "high breast density". High breast density is both an independent risk factor for breast cancer and masks cancers on a mammogram. Combined, these two distinct phenomena lead to increased incidence, delayed diagnosis, more aggressive tumours, and a 90% increased risk of breast cancer-associated death in women with high breast density.

    There is exciting potential for breast density to become a widespread health assessment tool, used to identify the women most at risk of breast cancer in order to intervene early and reduce that risk.

    Our research is the first to demonstrate a causal role for immune system signalling in breast density and the associated cancer risk. Using a unique human biobank of paired high and low density breast tissue samples, together with transgenic mouse models, we demonstrated that pro-inflammatory protein C-C Motif Chemokine Ligand 2 (CCL2) is a biological driver of both high breast density and increased risk of cancer. This study opens the door for new approaches to reduce breast cancer risk through use of anti-inflammatory drugs in women with dense breasts.

    Improving Breast Cancer Treatment

    Breaking immune tolerance in triple negative breast cancer: Failure of the body's immune system to attack a threat such as a mutated cell is known as immune tolerance, and is one of the key hurdles to overcome in both treating breast cancer and preventing its recurrence. Our laboratory has identified a new biological pathway active in breast cancer involving a protein called C1q, which can be targeted to break this tolerance. The aim of this project is to capitalize on this discovery to develop a new approach to breaking tolerance in triple negative cancer, a very aggressive subtype of breast cancer which is notoriously difficult to treat.

    Exploring the impact of menstrual cycling on personalised medicine for premenopausal breast cancer patients: Gene expression profiling of breast cancer is a technology increasingly being adopted in the clinic as a personalised medicine approach to tailor treatment to individual patients. However, an underappreciated factor in premenopausal breast cancer diagnosis is that oestrogen and progesterone fluctuate dramatically during the menstrual cycle, and these hormones are likely to affect gene expression. This research aims to determine whether fluctuation in oestrogen and progesterone associated with different stages of the menstrual cycle significantly affects gene expression profiles in breast cancers from premenopausal women. We will examine gene expression profiles in paired biopsy and surgical breast cancer tissue samples taken from women undergoing treatment at The Queen Elizabeth Hospital, and investigate how menstrual cycle stage in the two samples affects breast cancer subtype.

    Mastitis and Lactation Insufficiency

    Lactation mastitis is an inflammatory breast disease affecting 17-27% of ÐÓ°ÉÖ±²¥n breastfeeding women that causes pain, fever and low milk supply. The challenges posed by this disease lead many women to use supplementary formula, or cease breastfeeding altogether leaving their infants at increased risk of respiratory and gastrointestinal diseases as babies, and non-communicable diseases including heart disease, obesity, diabetes, cancer, allergies, asthma, mental illness and chronic lung, liver and renal diseases as both children and adults. Our recent research has suggested that macrophages play a role in development of this disease.


    Our current research pursues new knowledge in how disease state develop in the breast. We explore revolutionary new concepts of how immune cells function in the breast, and how these cells affect breast disease development.

     

     

     

  • Publications

  • Community Engagement

    InforMD: a new initiative to raise public awareness about breast density

    On a mammogram, breast density (also known as mammographic density) is shown as white and bright regions, and is associated with reduced sensitivity in cancer detection and increased breast cancer risk. However, many ÐÓ°ÉÖ±²¥n women are unaware of the significance of breast density as it is not routinely reported or discussed. To address this lack of knowledge, ÐÓ°ÉÖ±²¥n breast cancer researchers with expertise in mammographic density formed the InforMD alliance (INformation FORum on Mammographic Density) in 2016. The alliance is working to raise awareness of breast density with the goal of improving breast cancer diagnosis and health outcomes for women. The InforMD website (www.InforMD.org.au) was launched in October 2016, coinciding with a major nationwide public awareness campaign by the alliance during breast cancer awareness month. The website contains unbiased, accurate, updated information on breast density. The website also provides summaries of major research articles in layperson language, recent news items related to breast density, links to relevant information for health professionals, events, and feature articles. Members of the public and health professionals can also subscribe for news updates. The interactive online Forum section facilitates discussion between health professionals, scientists and members of the public. To increase online traffic to the website, Facebook (www.facebook.com/BeInforMD) and Twitter (https://twitter.com/BeInforMD_) pages were launched in December 2016. Since its launch, InforMD has generated considerable interest. The public awareness campaign reached over 7 million ÐÓ°ÉÖ±²¥ns through a combination of newspaper, TV, radio, and online news. The website has attracted over 70,000 page views and currently attracts 800 views per week (data as of 15/01/2019). Breast cancer researchers have a significant role to play in disseminating information to the public on breast density. A combination of mainstream and social media, together with a well-informed and updated website, has laid the groundwork for the InforMD alliance to reach a wide audience.

  • Files

The information in this directory is provided to support the academic, administrative and business activities of the ÐÓ°ÉÖ±²¥ of Adelaide. To facilitate these activities, entries in the ÐÓ°ÉÖ±²¥ Phone Directory are not limited to ÐÓ°ÉÖ±²¥ employees. The use of information provided here for any other purpose, including the sending of unsolicited commercial material via email or any other electronic format, is strictly prohibited. The ÐÓ°ÉÖ±²¥ reserves the right to recover all costs incurred in the event of breach of this policy.

Entry last updated: Tuesday, 29 Mar 2022

To link to this page, please use the following URL:  /directory/wendy.ingman